Search

Your search keyword '"VIVIAN FONSECA"' showing total 72 results

Search Constraints

Start Over You searched for: Author "VIVIAN FONSECA" Remove constraint Author: "VIVIAN FONSECA" Journal diabetes care Remove constraint Journal: diabetes care
72 results on '"VIVIAN FONSECA"'

Search Results

1. Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes

2. Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial

Catalog

Books, media, physical & digital resources

3. Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors

4. Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes

5. Diabetes INSIDE: Improving Population HbA1c Testing and Targets in Primary Care With a Quality Initiative

6. Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study

7. Post-ACA Racial Disparity of Eye Examinations Among the U.S. Noninstitutionalized Population With Diabetes: 2014–2015

8. Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes

9. Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306

10. Sex Differences in Cardiovascular Risk Profile From Childhood to Midlife Between Individuals Who Did and Did Not Develop Diabetes at Follow-up: The Bogalusa Heart Study

11. Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study

12. Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database

13. Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

14. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)

15. Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes

16. Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial

17. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

18. The American Diabetes Association Diabetes Research Perspective

19. Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes

20. Beyond the Monofilament for the Insensate Diabetic Foot

21. Hypoglycemia, Diabetes, and Cardiovascular Events

22. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

23. Bile Acids and Metabolic Regulation

24. Defining and Characterizing the Progression of Type 2 Diabetes

25. Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?

26. Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

27. The Role of Iron in Diabetes and Its Complications

28. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

29. Response to comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care 2015;38:1067-1074

30. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure

31. Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control

32. Association of Hypoglycemia and Cardiac Ischemia

33. Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment

34. Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes

35. Empirical Derivation to Improve the Definition of the Metabolic Syndrome in the Evaluation of Cardiovascular Disease Risk

36. Surge in newly identified diabetes among medicaid patients in 2014 within medicaid expansion States under the affordable care act

37. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes

38. Racial disparity of eye examinations among the U.S. working-age population with diabetes: 2002-2009

39. Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

40. Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults

41. The Hurricane Katrina Aftermath and Its Impact on Diabetes Care

42. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial

43. Decreasing Restenosis Following Angioplasty

45. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults

46. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

47. Translating the A1C Assay

49. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease

50. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes